Oncolytic Virus Therapies Market Size, Share, Growth And Forecast 2024-2032

Global Oncolytic Virus Therapies Industry: Key Statistics and Insights in 2024-2032

Summary:

• The global oncolytic virus therapies market size reached USD 162.7 Million in 2023.

• The market is expected to reach USD 709.0 Million by 2032, exhibiting a growth rate (CAGR) of 17.23% during 2024-2032.

• North America leads the market, accounting for the largest oncolytic virus therapies market share.

• The market is divided into two categories based on virus type: genetically engineered oncolytic viruses (herpes simplex virus, adenovirus, and vaccinia virus) and oncolytic wild-type viruses.

• The market is divided into two categories based on application: solid tumors (breast cancer, prostate cancer, lung cancer, glioblastoma, and melanoma) and hematological malignancies.

• The market is classified into three categories based on end use: hospitals, specialist clinics, and cancer research institutes.

• The increasing frequency of cancer worldwide is a major driver of the oncolytic virus therapeutics industry.

• The increased interest in combination medicines is altering the oncolytic virus therapy market.

Industry Trends and Drivers:

• Rising cancer incidence:

Oncolytic virus design and modification are being improved as genetic engineering and synthetic biology advance. This includes developing viruses with improved targeting capabilities, reduced toxicity to healthy cells, and higher reproduction within tumors. Nanoparticle carriers and tailored delivery technologies have improved the efficiency with which oncolytic viruses can be delivered directly to tumor locations. These technologies help to ensure that higher quantities of the therapeutic virus reach the tumor while limiting exposure to the rest of the body. New technologies provide more control over oncolytic virus therapy. This includes improved ways for tracking viral activity and evaluating responses in real time. As a result, therapies are safer and more effective.

• Growing interest in combination therapies:

Overall efficacy can be increased by combining oncolytic viruses with other therapeutic modalities such checkpoint inhibitors, chemotherapy, or targeted treatments. When used in conjunction with other treatments, oncolytic viruses not only kill cancer cells directly but also prime the immune system to more effectively identify and combat the tumor. Combining oncolytic viruses with additional medicines increases the likelihood of overcoming or avoiding these resistance mechanisms, which can lead to more effective and long-lasting responses in patients. This is because cancer cells can become resistant to single-agent treatments over time. Furthermore, oncolytic viruses have the ability to improve the conditions for other therapies. For example, viruses have the ability to release tumor antigens and kill cancer cells. By assisting the immune system in identifying cancer cells, this can strengthen immunotherapy.

• Technological advancements:

Synthetic biology and genetic engineering are helping to improve the design and modification of oncolytic viruses. This requires creating viruses that are more targetable, less damaging to healthy cells, and capable of reproducing within tumors. Direct administration of oncolytic viruses to tumour sites is becoming increasingly effective as delivery mechanisms evolve, including customized delivery approaches and nanoparticle carriers. By limiting exposure to the rest of the body, these approaches ensure that higher concentrations of the therapeutic virus reach the tumor. New technology allows for more control over oncolytic viral therapies. This includes cutting-edge methods for measuring viral activity and quickly analyzing reactions. Treatments are consequently safer and more effective.

Grab a sample PDF of this report: imarcgroup.com/oncolytic-virus-therapies-ma..

Oncolytic Virus Therapies Market Report Segmentation:

Breakup By Application:

• Solid Tumors

  • Breast Cancer

  • Prostate Cancer

  • Lung Cancer

  • Glioblastoma

• Melanoma

  • Hematological Malignancies

  • Lymphoma

  • Leukemia

  • Myeloma

Based on the application, the market has been classified into solid tumors (breast cancer, prostate cancer, lung cancer, glioblastoma, and melanoma) and hematological malignancies (lymphoma, leukemia, and myeloma).

Breakup By End Use:

• Hospitals

• Specialty Clinics

• Cancer Research Institute

On the basis of the end use, the market has been divided into hospitals, specialty clinics, and cancer research institute.

Breakup By Region:

• North America (United States, Canada)

• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)

• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

• Latin America (Brazil, Mexico, Others)

• Middle East and Africa

North America enjoys the leading position in the oncolytic virus therapies market due to its advanced healthcare infrastructure, substantial investment in research and development, and a high prevalence of clinical trials and regulatory support.

Top Oncolytic Virus Therapies Market Leaders:

The oncolytic virus therapies market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• Amgen Inc.

• Dnatrix Inc.

• Genelux Corporation

• Lokon Pharma AB

• Replimune Group Inc.

• Rigvir Ltd.

• Sorrento Therapeutics

• Takara Bio Inc. (Takara Holdings Inc.)

• Targovax

• TILT Biotherapeutics Ltd

• Transgene SA

• Vyriad

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145